Groundbreaking research has illuminated a significant correlation between the presence of obesity and an accelerated trajectory of Alzheimer’s disease pathology, as evidenced by novel blood-based biomarkers. A comprehensive investigation, the first of its kind to specifically examine how excess body weight influences these molecular indicators, revealed that individuals with obesity experienced a markedly faster elevation in Alzheimer’s disease blood biomarker (BBM) levels, with some markers increasing up to 95% more rapidly compared to their non-obese counterparts. These pivotal findings were recently unveiled at the annual meeting of the Radiological Society of North America (RSNA).
"This study marks a critical milestone, providing the initial empirical demonstration of the direct link between obesity and Alzheimer’s disease, quantified through the analysis of blood biomarker profiles," stated Dr. Cyrus Raji, a senior author on the study and a principal investigator within the Neuroimaging Labs Research Center at the Mallinckrodt Institute of Radiology (MIR) at Washington University School of Medicine in St. Louis. His sentiment underscores the novelty and significance of observing these molecular changes through accessible blood tests.
To meticulously investigate this intricate relationship, the research team leveraged an extensive five-year dataset comprising 407 volunteers who were participants in the Alzheimer’s Disease Neuroimaging Initiative (ADNI). This initiative provided a rich repository of longitudinal data, encompassing both amyloid positron emission tomography (PET) scans and serial blood samples. Amyloid PET imaging plays a crucial role in visualizing the extent of amyloid burden within the brain, which refers to the accumulation of beta-amyloid protein fragments that coalesce into amyloid plaques—a hallmark pathological feature of Alzheimer’s disease.
The analytical process involved the detailed examination of plasma samples for a spectrum of BBMs intrinsically associated with Alzheimer’s disease. Among these were levels of phosphorylated tau 217 (pTau217), a highly sensitive biomarker instrumental in the diagnosis and ongoing monitoring of Alzheimer’s disease progression. Also analyzed was neurofilament light chain (NfL), a protein fragment released into the bloodstream when neurons undergo damage or degeneration, serving as an indicator of neuronal injury. Furthermore, plasma glial fibrillary acidic protein (GFAP) was assessed; GFAP is a protein predominantly expressed by astrocytes, the crucial support cells that maintain the health and function of neurons within the central nervous system. The study utilized six leading commercial testing platforms to ensure the robustness and reproducibility of these biomarker measurements.
The researchers employed sophisticated statistical methodologies to ascertain the precise nature of the association between these BBMs and body mass index (BMI), a widely recognized metric for assessing body weight relative to height. A key focus was evaluating a complex, three-way interaction involving baseline obesity status, the passage of time, and the observed changes in BBM levels. Crucially, these findings derived from blood analyses were systematically compared and corroborated against the independent data obtained from amyloid PET scans, thereby enhancing the validity of the conclusions.
An initial observation, upon combining the blood and imaging data, indicated that at the commencement of the study, individuals with higher BMIs tended to exhibit lower baseline levels of certain BBMs and a reduced overall amyloid burden across their brains. Dr. Soheil Mohammadi, the lead author of the study and a postdoctoral research associate at MIR, offered a compelling explanation for this initial discrepancy. "We hypothesize that the lower BBM concentrations observed in individuals with obesity at baseline are attributable to a dilution effect stemming from their higher blood volume," he explained. He further elaborated on the potential pitfalls of relying solely on these initial measurements: "Indeed, if one were to exclusively consider the baseline data, it might lead to an erroneous conclusion that individuals with obesity possess a less severe Alzheimer’s disease pathology. It is only through the utilization of longitudinal data that we can truly grasp the multifaceted ways in which obesity influences the development of Alzheimer’s pathology." This emphasis on longitudinal data collection, which involves repeatedly gathering information from the same individuals over extended periods to track evolving trends, is paramount for understanding dynamic biological processes.
The temporal progression of the disease revealed a starkly different picture. As the study progressed over several years, both the Alzheimer’s disease BBMs and the results from brain PET scans demonstrated a significantly greater accumulation of Alzheimer’s-related pathological changes in participants classified as having obesity, when contrasted with those who did not. Specifically, individuals with obesity experienced a substantially faster rate of increase in plasma pTau217 ratio levels, ranging from a 29% to a remarkable 95% acceleration. Furthermore, the presence of obesity at the study’s outset was correlated with a 24% faster rise in plasma NfL, indicative of accelerated neuronal damage, and a 3.7% more rapid accumulation of amyloid in the brain.
Dr. Raji highlighted a particularly striking revelation from their findings: blood tests demonstrated a superior sensitivity in detecting the influence of obesity on Alzheimer’s-related brain alterations compared to PET scans. "The fact that we can track the predictive impact of obesity on escalating blood biomarkers with greater sensitivity than PET is what truly astonished us in this study," he remarked, emphasizing the diagnostic potential of these accessible and less invasive tests.
The clinical implications of these findings are profound, particularly concerning how healthcare professionals assess and manage the risk of Alzheimer’s disease. Dr. Mohammadi underscored the significance of obesity as a modifiable risk factor. "According to the comprehensive 2024 report by The Lancet Commission, a substantial proportion of Alzheimer’s disease risk—approximately 45%, or nearly half—is attributable to 14 modifiable risk factors," he noted. "Consequently, any successful intervention to mitigate these risk factors holds the potential to significantly reduce the incidence of Alzheimer’s disease or substantially delay its onset." This highlights a critical window of opportunity for preventative strategies.
Looking towards the future, the researchers foresee a transformative role for repeated measurements of blood biomarkers, especially when integrated with advanced brain imaging techniques, in the monitoring of treatment strategies, particularly those involving novel anti-amyloid therapies. Dr. Raji expressed optimism about the potential synergy between advancements in obesity treatment and Alzheimer’s research. "This area of scientific inquiry is incredibly exciting at present, particularly because we now possess highly effective medications for managing obesity. This opens up avenues for future studies to meticulously track the impact of weight loss interventions on Alzheimer’s biomarkers," he stated. He further emphasized the synergistic power of modern diagnostic tools: "It is truly remarkable that we have these blood biomarkers to track the molecular underpinnings of Alzheimer’s disease, complemented by MRI scans that provide additional evidence of brain degeneration and the efficacy of various therapeutic interventions. This body of work serves as a foundational pillar for subsequent research endeavors and clinical trials." The collaborative efforts of Farzaneh Rahmani, M.D., M.P.H., Mahsa Dolatshahi, M.D., M.P.H., and Suzanne E. Schindler, M.D., Ph.D., were also instrumental in this significant research undertaking.
About the Author
